184 related articles for article (PubMed ID: 9754948)
1. The antiviral activity of the ribonucleotide reductase inhibitor BILD 1351 SE in combination with acyclovir against HSV type-1 in cell culture.
Lawetz C; Liuzzi M
Antiviral Res; 1998 Jul; 39(1):35-46. PubMed ID: 9754948
[TBL] [Abstract][Full Text] [Related]
2. Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo.
Duan J; Liuzzi M; Paris W; Lambert M; Lawetz C; Moss N; Jaramillo J; Gauthier J; Déziel R; Cordingley MG
Antimicrob Agents Chemother; 1998 Jul; 42(7):1629-35. PubMed ID: 9660995
[TBL] [Abstract][Full Text] [Related]
3. The synergistic effects of betulin with acyclovir against herpes simplex viruses.
Gong Y; Raj KM; Luscombe CA; Gadawski I; Tam T; Chu J; Gibson D; Carlson R; Sacks SL
Antiviral Res; 2004 Nov; 64(2):127-30. PubMed ID: 15498608
[TBL] [Abstract][Full Text] [Related]
4. Resistance of herpes simplex virus type 1 to peptidomimetic ribonucleotide reductase inhibitors: selection and characterization of mutant isolates.
Bonneau AM; Kibler P; White P; Bousquet C; Dansereau N; Cordingley MG
J Virol; 1996 Feb; 70(2):787-93. PubMed ID: 8551616
[TBL] [Abstract][Full Text] [Related]
5. Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase: a new class of antiviral agents.
Moss N; Beaulieu P; Duceppe JS; Ferland JM; Gauthier J; Ghiro E; Goulet S; Grenier L; Llinas-Brunet M; Plante R
J Med Chem; 1995 Sep; 38(18):3617-23. PubMed ID: 7658449
[TBL] [Abstract][Full Text] [Related]
6. Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir.
Spector T; Lobe DC; Ellis MN; Blumenkopf TA; Szczech GM
Antimicrob Agents Chemother; 1992 May; 36(5):934-7. PubMed ID: 1324641
[TBL] [Abstract][Full Text] [Related]
7. Lactoferrin and lactoferricin inhibit Herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir.
Andersen JH; Jenssen H; Gutteberg TJ
Antiviral Res; 2003 May; 58(3):209-15. PubMed ID: 12767468
[TBL] [Abstract][Full Text] [Related]
8. Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
Chen H; Teng L; Li JN; Park R; Mold DE; Gnabre J; Hwu JR; Tseng WN; Huang RC
J Med Chem; 1998 Jul; 41(16):3001-7. PubMed ID: 9685239
[TBL] [Abstract][Full Text] [Related]
9. Synergistic inhibition of herpesvirus replication by docosanol and antiviral nucleoside analogs.
Marcelletti JF
Antiviral Res; 2002 Nov; 56(2):153-66. PubMed ID: 12367721
[TBL] [Abstract][Full Text] [Related]
10. The ribonucleotide reductase inhibitor (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731): a potential topical therapy for herpes simplex virus infection.
Bridges CG; Ahmed SP; Sunkara PS; McCarthy JR; Tyms AS
Antiviral Res; 1995 Aug; 27(4):325-34. PubMed ID: 8540753
[TBL] [Abstract][Full Text] [Related]
11. Viral ribonucleotide reductase attenuates the anti-herpes activity of acyclovir in contrast to amenamevir.
Shiraki K; Tan L; Daikoku T; Takemoto M; Sato N; Yoshida Y
Antiviral Res; 2020 Aug; 180():104829. PubMed ID: 32569704
[TBL] [Abstract][Full Text] [Related]
12. A new homodimer of aciclovir as a prodrug with increased solubility and antiviral activity.
Brandi G; Rossi L; Schiavano GF; Millo E; Magnani M
Int J Antimicrob Agents; 2009 Aug; 34(2):177-80. PubMed ID: 19394201
[TBL] [Abstract][Full Text] [Related]
13. Combined effects of interferon-alpha and acyclovir on herpes simplex virus type 1 DNA polymerase and alkaline DNase.
Taylor JL; Tom P; O'Brien WJ
Antiviral Res; 1998 May; 38(2):95-106. PubMed ID: 9707372
[TBL] [Abstract][Full Text] [Related]
14. A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo.
Liuzzi M; Déziel R; Moss N; Beaulieu P; Bonneau AM; Bousquet C; Chafouleas JG; Garneau M; Jaramillo J; Krogsrud RL
Nature; 1994 Dec; 372(6507):695-8. PubMed ID: 7990963
[TBL] [Abstract][Full Text] [Related]
15. Expression of herpes simplex virus type 1 recombinant thymidine kinase and its application to a rapid antiviral sensitivity assay.
Shiota T; Lixin W; Takayama-Ito M; Iizuka I; Ogata M; Tsuji M; Nishimura H; Taniguchi S; Morikawa S; Kurane I; Mizuguchi M; Saijo M
Antiviral Res; 2011 Aug; 91(2):142-9. PubMed ID: 21669227
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of antiherpetic activity of acyclovir by ribonucleotide reductase inhibition.
Spector T; Averett DR; Nelson DJ; Lambe CU; Morrison RW; St Clair MH; Furman PA
Proc Natl Acad Sci U S A; 1985 Jun; 82(12):4254-7. PubMed ID: 2987969
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effects of acyclovir and 3, 19-isopropylideneandrographolide on herpes simplex virus wild types and drug-resistant strains.
Priengprom T; Ekalaksananan T; Kongyingyoes B; Suebsasana S; Aromdee C; Pientong C
BMC Complement Altern Med; 2015 Mar; 15():56. PubMed ID: 25879785
[TBL] [Abstract][Full Text] [Related]
18. Synergistic in vitro interactions between (22S,23S)-3beta-bromo-5alpha,22,23-trihydroxystigmastan-6-one and acyclovir or foscarnet against herpes simplex virus type 1.
Talarico LB; Castilla V; Ramirez JA; Galagovsky LR; Wachsman MB
Chemotherapy; 2006; 52(1):38-42. PubMed ID: 16340198
[TBL] [Abstract][Full Text] [Related]
19. A screening dye-uptake assay to evaluate in vitro susceptibility of herpes simplex virus isolates to acyclovir.
Danve C; Morfin F; Thouvenot D; Aymard M
J Virol Methods; 2002 Sep; 105(2):207-17. PubMed ID: 12270654
[TBL] [Abstract][Full Text] [Related]
20. Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication.
Luganini A; Sibille G; Mognetti B; Sainas S; Pippione AC; Giorgis M; Boschi D; Lolli ML; Gribaudo G
Antiviral Res; 2021 May; 189():105057. PubMed ID: 33716051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
